-
Green leaf pharmaceutical high-dose Liss' permeable skin patch has been approved for sale in Germany
Time of Update: 2021-02-24
's single-day permeable patch for the treatment of Alzheimer's disease is one of the core products of Leafy Pharmaceuticals in the central nervous field.
Green leaf pharmaceutical's Liss's single-day permeable patch was developed by its German subsidiary, Luye Pharma AG, on the research and development platform for permeable drugs.
-
Novaral's sickle cell drug gets FDA priority review
Time of Update: 2021-02-24
The regulatory agency accepted the company's Biologics Licensing Application (BLA) for the prevention of vascular ococcytosis (VOCs) in patients with sickle cell disease (SCD) and was awarded a breakthrough treatment designation in December 2018.
-
Breyanzi, the CAR-T cell therapy of Shishi Shiguibo, has been approved by the FDA
Time of Update: 2021-02-24
, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's CD19 CAR-T cell therapy, Breyanzi (lisocabtagene maraleucel, liso-cel) for the treatment of adult patients with recurring or incurable large B-cell lymphoma treated in two or more systemic treatments.
-
Concorde Kirin pioneered the clinical success of ox40-targeted single-anti-KHK4083 Phase II
Time of Update: 2021-02-23
Japanese pharmaceutical company Kyowa Kirin recently announced that phase 2 studies evaluating the antibody drug KHK4083 for moderate to severe specific dermatitis (AD) adult patients have reached the main endpoint.
-
Allogeneic stem cell therapy! Takeda Darvadstrocel Japan applied for listing
Time of Update: 2021-02-23
Takeda recently announced that it has submitted an application to Japan's Ministry of Health, Labour and Labour (MHLW) to produce and sell darvadstrocel (development code: Cx601) for the treatment of complex fistula in adult patients with in activity/mild active tube crohn's disease (CD).
-
Renal transparent cell carcinoma immune escape "culprit" identified
Time of Update: 2021-02-23
Xu Jiejie said, however, in the process of triggering renal transparent cell carcinoma immune escape, the specific cells, factors and pathlines play a key role, how to combine immunotherapy to enable CXCL13 protein and CD8 protein double-positive T cells to re-perform the "responsibility" of anti-tumor immune response, is still under further exploration.
-
Cao Xuetao first mentioned the new concept of "look-a-view meta-control group"
Time of Update: 2021-02-23
Cao Xuetao introduced, this review focuses on this new concept, systematically expounds how the micro-environmental signals of tissue organs in the process of cell differentiation, development and stress can be constructed by constructing the cell "look-off metacontrolling group" to build the characteristic functional state of natural immune cells, so as to accurately regulate the natural immune and inflammatory response.
-
Be careful of caffeine in the womb
Time of Update: 2021-02-23
new study is unique in that researchers have found a different biological path in the brains of children exposed to caffeine during pregnancy.
-
Gilead and HHS have launched a free drug program
Time of Update: 2021-02-22
Related: Gilead's Descovy Gets Drug License Next: Convert Truvada Patients As part of the plan, HHS will pay Gilead $200 per bottle of 30 pills by March 30 to cover shipping costs, according to the New York Times.
-
FDA approves use of Vascepa-assisted therapy to reduce the risk of cardiovascular disease
Time of Update: 2021-02-22
about the Vascepa Vascepa is the first FDA-approved complementary therapy to be used as a maximum to-dosage statin to reduce triglyceride levels and increase the risk of cardiovascular disease in patients.
Vascepa has been approved by the FDA to reduce triglyceride levels in patients with severe high triglycerides.
-
Three generic applications for Novarma generic Gilenya have been approved by the FDA
Time of Update: 2021-02-22
Gilenya is understood to have received FDA approval for the first time in 2010 to treat adults with relapsed sclerosis.
In addition, Gilenya may increase the risk of serious infection, so patients need to be monitored for infection during treatment and two months after suspension.
-
Sanofi insulin insulin injection glycodes was approved by the FDA
Time of Update: 2021-02-22
recently, Sanofi announced that its insulin glaucin injection, Toujeo, has FDA approval to treat children with type 1 diabetes aged 6 years and older.
-
FDA approves first targeted treatment for rare Duxing muscular dystrophy
Time of Update: 2021-02-22
With today's accelerated approval, patients with Duxing, a rare and devastating disease, can skip Vyondys 53 if their muscular dystrophy protein gene is confirmed to have mutated, and will now receive the first treatment specifically for the disease subtype," the FDA said.
-
FDA approves Amrin fish oil product extension adaptation
Time of Update: 2021-02-22
Vascepa is the first FDA-approved complementary therapy to be used as a maximum to-dosage statin to reduce triglyceride levels and increase the risk of cardiovascular disease in patients.
-
Roche Xofluza has increased drug resistance but is not good for children
Time of Update: 2021-02-22
The team tested H3N2 samples from 40 adults and H3N2 samples from 101 children before treatment, and found that two of the flu patients with drug-resistant mutations were children.
-
Breast cancer HER2 target re-explosion of new drug data more than 80% efficiency
Time of Update: 2021-02-22
DESTINY-Breast01 is a key Phase II, single-arm, open-label, global, multi-center, two-part clinical trial designed to assess the safety and efficacy of DS-8201 in her2-positive non-excisive and/or metastasis breast cancer patients who have previously received trictiles monoantigen-metan new joint therapy.
-
Johnson and Johnson Darzalex reduces risk of death in new myeloma patients by 40%
Time of Update: 2021-02-22
In a phase III study of previously untreated myeloma patients, adding Darzalex to a combined drug in Mifalon, Pernisson and Takeda reduced the risk of death by 40 percent, Johnson and Johnson's Jean Sang said at the annual meeting of the American Society of Hematology.
-
The phase 3 trial of CC-486 maintenance therapy obtained positive results
Time of Update: 2021-02-22
Today, As a maintenance therapy, CC-486 achieved statistically and clinically significant improvements in total survival (OS) and recurrence (RFS) compared to placebos in phase 3 critical trial QUAZAR AML-001 for patients treating acute myeloid leukemia (AML).
-
Pfizer announces that the second generation of EGFR-Tyrosine kinase inhibitors has landed in China
Time of Update: 2021-02-22
On May 15 this year, dacotinib tablets were approved by China's State Drug Administration (NMPA) and can be used for first-line treatment in patients with partial late stage or metastasis non-small cell lung cancer (NSCLC) patients with exosome loss mutation No. 19 exosome 19 or exon L858R replacement mutation No. 21.
-
The three companies have jointly conducted clinical trials of antibody-coupled drugs to treat urethra skin cancer
Time of Update: 2021-02-22
recently, Seattle Genetics and Astellas announced a partnership agreement with Mercedon to jointly conduct clinical trials of the antibody conceding drug (ADC) Enfortumab Vedotin and Keytruda for the first-line treatment of locally advanced or metastatic urethra cancer.
